Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Kratom Regulation topic
No spam. Unsubscribe anytime.
Mixed testimony on kratom bill as health officials and advocates disagree on product limits
Summary
At a packed hearing, witnesses for and against SB463—proposed regulation requiring registration and labeling for kratom products—testified on health uncertainties, market safety and the need for state rules in the absence of federal regulation.
The Senate Health and Human Services committee and the Committee on CPN heard SB463, a bill proposing registration and labeling requirements for kratom products, including potency limits and restrictions on certain drug‑interaction formulations. The Department of Health testified in opposition, saying the agency lacks sufficient evidence to set safe levels and that a regulatory program would be premature.
Why it matters: Kratom is an herbal product with a range of reported uses and concerns. Proponents of regulation, including the American Kratom Association and some vendors, asked the Legislature to adopt a regulatory framework comparable to other states that ban adulteration, require product testing and set labeling and age restrictions. Opponents, including some public health advocates and Kratom Danger Awareness, warned about safety risks and urged different regulatory approaches.
Key testimony and concerns: Department of Health representative Matthew Carano told the committee the department “does not know what safe levels are” and recommended further study before creating a registration regime. The Global Kratom Coalition urged removal of two provisions it called problematic: a production/marketing‑based loophole to the 2% 7‑hydroxy mitragynine upper limit and a prohibition on combining kratom with P450‑inhibiting compounds, which the coalition said would create an unprecedented and costly oversight bureaucracy. The American Kratom Association argued Hawaii could join 13 other states by setting product limits, labeling and age restrictions and said the state could benefit as a supplier of kratom raw material.
Public comment included individual users who said kratom provided relief from chronic pain and opioid dependence; one testifier described life‑changing pain relief after switching to kratom tea. Opponents raised concerns about product adulteration, unknown dose‑response and drug interaction risks.
Committee action: Committee chairs implemented a one‑minute cap on oral testimony because the earlier agenda ran long and asked stakeholders to submit written testimony for the record. No final vote on SB463 was recorded during this hearing; chairs said they would accept written comments and continue deliberations.
